Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients: a randomised, open-label, multicentre study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)

European Association of Urology (The Netherlands)0 个研究点目标入组 1,300 人开始时间: 2005年12月19日最近更新: 2015年1月13日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 1,300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: Male

入选标准

•1. Male patients aged 18+ years, Eastern Cooperative Oncology Group (ECOG) = 0 (Karnofsky performance status greater than 90)
•2. M0 prostate cancer patients who previously received local curative treatment (e.g. surgery, radiotherapy) or no local curative treatment. Duration between local curative treatment and starting of the study drug must not be longer than 6 months.
•3. At least one of the following conditions must be present:
•3.1. Gleason Score 8 - 10
•3.2. pN+
•3.3. Prostate specific antigen (PSA) equal to or higher than 20 ng/ml at diagnosis
•4. Patients receiving androgen deprivation by orchiectomy or administration of GnRH analogue ± anti-androgens or no androgen deprivation. Hormone therapy regimen will depend on standard medical management of prostate cancer patients i.e. when corresponding to standard medical management, patients on hormone treatment at study entry can later be withdrawn and patients not on hormone treatment at study entry can later start with androgen deprivation. Intermittent hormone treatment is allowed when corresponding to standard medical management. Patients should not be under hormonal ablation for longer than 6 months before the first study drug infusion. Neoadjuvant androgen deprivation is allowed as long as the duration between start of androgen deprivation and start of study drug is no longer than 6 months.
•5. Life expectancy of greater than 6 months
•6. Signed informed consent prior to initiation of any study procedure

排除标准

•1. Patients with known visceral metastasis or bone metastases in bone scan
•2. Prior treatment with bisphosphonates
•3. Chemotherapy to treat prostate carcinoma
•4. Anti-androgen monotherapy is not allowed
•5. Use of other investigational drugs (drugs not marketed for any indication) within 6 months before start of study
•6. History of noncompliance to medical regimens and patients who are considered potentially unreliable or incapable of giving informed consent as judged by the investigator
•7. Serum creatinine greater than 3 mg/dl (265 µmol/l)
•8. History of other malignant neoplasm within previous five years with exception of non-melanomatous skin cancer which has been satisfactorily treated
•9. Other known concurrent, severe medical disorder jeopardising the life of the patient in the immediate future (myocardial infarction in previous six months, angina pectoris despite treatment, uncontrolled severe arterial hypertension, progressive cardiac or respiratory failure)

研究者

发起方

European Association of Urology (The Netherlands)

相似试验

已完成

3 期

Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patientsC61Malignant neoplasm of prostateprostate cancer

DRKS00004981European Association of Urology1,433

进行中（未招募）

不适用

Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)Prevention of bone metastasis in high risk prostate cancer patients.MedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2004-001786-18-ITEAU EUROPEAN ASSOCIATION OF UROLOGY1,300

已完成

4 期

Zinthoma, Antiretroviral and Nausea and VomitingHIV/AIDS.Human immunodeficiency virus [HIV] diseaseB20-B24

IRCT201305283449N12Tehran University of Medical Sciences80

终止

3 期

ZOMETA® (Zoledronic Acid) for Prevention of Bone MetastasesProstate Cancer

NCT00294437Central European Cooperative Oncology Group376

已完成

2 期

Effect of acetazolamide on the prevention of cerebrospinal fluid leakage after spinal surgeryDura damage.Cerebrospinal fluid leak from spinal puncture

IRCT201501178612N2Pharmaceutical care department-Shariati Hospital70